DiabetologyNews.net

Diabetology Xagena

Search results for "Sitagliptin"

Results from three Phase II studies showed that Sitagliptin ( Januvia ), an investigational medicine in a potentially new class of agents for the treatment for diabetes called DPP-IV ( dipeptidyl pep ...


Phase III studies demonstrated that Sitagliptin ( Januvia ), an investigational oral, once-daily medicine for type 2 diabetes, significantly reduced blood glucose levels when used as monotherapy or as ...


Positive top-line results of two additional phase III AWARD trials for Dulaglutide, an investigational, long-acting glucagon-like peptide 1 ( GLP-1 ) receptor agonist being studied as a once-weekly tr ...


The results of a 24-week phase III clinical trial, which showed that treatment with the investigational compound Empagliflozin as monotherapy produced statistically significant reductions in HbA1c ver ...


The EMA ( European Medicines Agency ) is investigating findings by a group of independent academic researchers that suggest an increased risk of pancreatitis ( inflammation of the pancreas ) and preca ...


The FDA ( Food and Drug Administration ) has approved Invokana ( Canagliflozin ) for the treatment of adults with type 2 diabetes. Invokana is the first in a new class of medications called sodium glu ...


The aim of the study was to investigate the long-term safety and efficacy of Empagliflozin ( Jardiance ), a sodium glucose cotransporter 2 inhibitor ( SGLT2 ); Sitagliptin ( Januvia ); and Metformin ( ...


The aim was to assess the efficacy and safety of Dapagliflozin ( Forxiga ) as add-on therapy in patients with type 2 diabetes who were inadequately controlled with a dipeptidyl peptidase-4 inhibitor w ...


Results from an observational study that has assessed the differences in time to initiation of Insulin use and the proportion of the population initiating Insulin among patients with type 2 diabetes t ...


An observational study has shown that patients with type 2 diabetes mellitus treated with a combination of Sitagliptin and Metformin initiated Insulin therapy at a slower rate during the period of obs ...


Omarigliptin, an investigational once-weekly DPP-4 inhibitor in development for adults with type 2 diabetes, has achieved its primary efficacy endpoint in a phase 3 study. Omarigliptin was found to be ...


Patients with type-2 diabetes and cardiovascular disease can safely take the antihyperglycemic drug Sitagliptin ( Januvia ) without an increased risk of cardiovascular complications, even if they have ...


Findings from two phase 3a clinical trials for Semaglutide, an investigational glucagon-like peptide-1 ( GLP-1 ) analogue, were presented at the American Diabetes Association ( ADA ) 76th Scientific S ...